TheProfitWatch

KLTO - Klotho Neurosciences, Inc. Common Stock

Day 1m 10m 60m PreMarket Market AfterHours Gap
0.4 0.07 (17.91%) 0.0 (0.0%) 0.0 (0.15%) 0.01 (2.96%) 0.01 (3.29%) 0.06 (14.13%) 0.0 (-0.25%) 0.01 (3.42%)

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Category: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Market Period: Market

Earnings & Ratios

Basic EPS:
-0.12
Diluted EPS:
-0.12
Basic P/E:
-3.9451
Diluted P/E:
-3.9451
RSI(14) 1m:
63.38
VWAP:
0.47
RVol:

Events

Period Kind Movement Occurred At

Related News